| Literature DB >> 33838669 |
Xiaobo Zhu1,2, Chien-Wei Lee1,2,3, Hongtao Xu2, Yu-Fan Wang2, Patrick S H Yung2, Yangzi Jiang1,3, Oscar K Lee4,5,6,7.
Abstract
OBJECTIVE: Osteoarthritis (OA) has long been regarded as a disease of cartilage degeneration, whereas mounting evidence implies that low-grade inflammation contributes to OA. Among inflammatory cells involved, macrophages play a crucial role and are mediated by the local microenvironment to exhibit different phenotypes and polarization states. Therefore, we conducted a systematic review to uncover the phenotypic alterations of macrophages during OA and summarized the potential therapeutic interventions via modulating macrophages.Entities:
Keywords: Immunomodulation; Innate immunity; Macrophage; Osteoarthritis
Year: 2021 PMID: 33838669 PMCID: PMC8035781 DOI: 10.1186/s13075-021-02457-3
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Fig. 1Flowchart of studies included in the systematic review. After the application of all inclusion and exclusion criteria, 28 studies were identified for analysis
Characteristics and major conclusion of included studies
| Author | Cell source | Species | Study type | Conclusions |
|---|---|---|---|---|
| Mahon et al. [ | PBMC | Human | In vitro | BCP promotes macrophage M1 polarization during OA pathogenesis 2DG reverses BCP-induced M1 polarization in OA |
| Zhou et al. [ | RAW264.7 | Mouse | In vitro | ACLT model induces an increase of M1 polarization in synovial macrophage. Kin attenuates the number of M1 macrophage and up-regulated the M2 macrophage. |
| Jablonski et al. [ | N/A | Mouse | In vivo | The predominant macrophage population observed in uninjured knee joint is M1 macrophage. |
| Benjamin et al. [ | N/A | Dog | In vivo | CR (cruciate rupture) model leads to a M1 polarization in synovial macrophage. |
| Haltmayer et al. [ | N/A | Horse | In vitro | The osteochondral-synovial explant co-culture OA-model indicates a shift towards M1 phenotype during OA progression |
| Liu et al. [ | Synovial fluid; PBMC | Human | Human knee synovial macrophage displays an increased M1 polarization and decreased M2 polarization. | |
| Sambamurthy et al. [ | N/A | Mouse | In vivo | DMM model presents an elevated M1 polarization and decreased M2 polarization during OA progression |
| Wang et al. [ | BMMC | Mouse | In vivo | DMM model demonstrates increased numbers of M1 macrophages and decreased number of M2 macrophage. BTZ could reversed this pathological process |
| Zhang et al. [ | Synovium | Mouse | In vivo | Both human OA and CIOA model display an elevated M1 polarization |
| Timur et al. [ | Hoffa’s fat pad | Human | In vivo | PGE2 released by OA HFP is positively associated with M1 macrophages polarization, indicating a role for macrophages. Celecoxib modulated the inflammation ratio towards a more favorable anti-inflammatory M2 phenotype |
| Topoluk et al. [ | Synovium and cartilage explant | Human | In vitro | OA coculture of synovium with cartilage demonstrates increased M1 polarization. |
| Wu et al. [ | N/A | Mouse | In vivo | DMM model demonstrates increased numbers of M1 macro |
| Manferdini et al. [ | Human SMMC & PBMC | Human | In vitro | ASCs are responsible for the switching of activated-M1-like inflammatory macrophages to a M2-like phenotype |
| Pal et al. [ | PBMC | Human | In vitro | SFN could shift monocyte/macrophage differentiation towards the anti-inflammatory M2 type |
| Siebelt et al. [ | Human monocyte | Rat | In vitro | TA induces a M2 polarization in macrophage |
| Fahy et al. [ | SMMC and fibroblast | Human | In vitro | M1 macrophages downregulate MSC chondrogenesis |
| Tsuneyoshi et al. [ | N/A | Human | In vitro | The distribution and M1/M2 expression profiles of synovial macrophages are different between OA and RA synovium. |
| Zhang et al. [ | N/A | Rat | In vivo | In a Rat osteochondral defect model, M2 macrophages in cartilage and synovium increase. The intervention of exosomes increases the M2 macrophages and decreases M1 macrophage |
| Hu et al. [ | N/A | Rat | In vivo | Quercetin promotes cartilage repair by modulating macrophages polarization to M2 macrophages in Rat OA model |
| Dai et al. [ | RAW264.7 | Rat | In vivo | SCII immunomodulates a phenotype shift of macrophages from M0 to M2 during OA progression |
| Barreto et al. [ | PBMC | Human | In vitro | Lumican contributes to the innate immune-mediated pathogenesis of primary IOA via macrophage M1 polarization |
| Kraus et al. [ | N/A | Human | In vivo | One patient OA synovium presents M1 and M2 marker simultaneously. |
| Utomo et al. [ | PBMC | Human | In vitro | Dexamethasone lowers M1/M2 proportion in OA synovium. |
| Perla et al. [ | THP-1 cell; PBMC | Human | In vitro | Overexpression of CD163 contributes the transition from M1 to M2 when stimulated with LPS |
| Nobuaki et al. [ | N/A | Mouse | In vivo | Polarization towards M2-like macrophages from M1-like macrophages in the synovium is associated with OA alleviation by SRT2104. |
| Menarim et al. [ | BMMC | Horse | In vitro | BMNCs cultured in normal synovial fluid or inflamed synovial fluid exhibit aspects of both M1 and M2 phenotypes and immunoregulatory response. |
| Zhou et al. [ | RAW264.7 | Mouse | In vivo | Modified Nanoparticles suppress M1 macrophages and upregulate M2 macrophage infiltration in the synovium, thus preventing cartilage degeneration |
| Shu et al. [ | N/A | Mouse | In vivo | Hyaluronan could increase the anti-fibrotic M2c macrophages (F4/80+CD206+CD301+) 12 weeks post DMM |
Abbreviations: PBMC peripheral blood monocytes, SMM synovium-derived macrophage, BMMC bone marrow mononuclear cells
Fig. 2Characteristic outcomes of experimental species, animal models, and species distribution in animal interventional studies. a The proportion of experimental species. 43% studies (12/28) were based on primary cells or samples from human. 32% studies (9/28) were based on primary cells or samples from mice. 14% studies (4/28) were based on primary cells or samples from rats. 11% of studies (3/28) were based on samples from canine and equinel; b Pie chart illustrating the types of animal models used in the studies. 36% the animal models were ACLT (4/11). 36% the animal models were DMM (4/11). 18% the animal models were intra-articular injection of collagenase (2/11). 9% the animal models were other animal models including osteochondral defect model (1/11); c Species distribution in interventional animal studies. 64% the interventional studies were based on mouse models. 36% the interventional studies were based on rat models
Fig. 3Interventional subcategories. The interventions against OA included traditional Chinese herb extracts, anti-inflammation drugs, MSC-related therapy, targeting molecular modifications, and others
Details of the interventions in the included studies
| Author | Category | Intervention | Detected marker | Interventional site |
|---|---|---|---|---|
| Jablonski et al. [ | Endogenous molecule | Cartilage regeneration model; Cartilage regeneration model in CCR2−/−CCL2−/− mouse | Cartilage regeneration model: M1: CD38+↑; Cartilage regeneration model in CCR2−/−CCL2−/− mouse: M2:CD206+F4/80+↑ | Joint |
| Zhang et al. [ | Mouse OA model; Rheb1 Knockout (KO) in myeloid cells | Mouse OA model: M0: F4/80↑; M1: iNOS↑; Mouse OA model in Rheb1 KO mouse: M0: (F4/80↑)↓; M1: (iNOS↑)↓; M2: CD206↑ | Joint | |
| Zhou et al. [ | Mouse OA model; Modified ZIF-8 Nanoparticles | Mouse OA model: CD16/32↑; Nanoparticles on OA model: (CD16/32↑) ↓, CD163↑ | Joint | |
| Nobuaki et al. [ | Mouse OA model; SRT2104 (SIRT1 activator) | SRT2104 on OA model: M1: iNOS↓; M2: CD206↑ | Joint | |
| Siebelt et al. [ | Anti-inflammation | Triamcinolone acetonide (TA) | TA: M2: CD163↑ | Joint |
| Zhang et al. [ | MSC-related option | Exosomes | Rat OA model: M1: CD86↑; M2: CD163↓; Exosome + Rat OA model: (M1: CD86↑) ↓; (M2: CD163↓) ↑ | Joint |
| Shu et al. [ | Mouse OA model; Bone marrow stem cell (BMSC) | Hyaluronan:M2c (F4/80+CD206+CD301+)↑ | Joint | |
| Zhou et al. [ | Traditional Chinese herb | Kinsenoside (Kin) | Mouse OA model: M1: CD16/32 + ↑; Kin+ Mouse OA model: (M1: CD16/32 + ↑) ↓; M2: CD206↑ | Joint |
| Hu et al. [ | Quercetin | Quercetin: M2: Arg1↑, MR↑, Ym1↑; Rat OA model: M0: CD68↑; M2: MR↑; Quercetin+ Rat OA model: (M0: CD68↑) ↓; (M2: MR↑) ↑ | Joint | |
| Dai et al. [ | Squid type II collagen (SCII) | SCII: M2: Arg1↑, Ym1↑, MR↑, Fizz1↑; Rat OA model: M0: CD68↑; M2: MR↑; SCII+ Rat OA model: M0:(CD68↑) ↓; M2: (MR↑)↑ | Joint | |
| Wang et al. [ | Others | Mouse OA model Bortezomib (BTZ) | Mouse OA model: M1: F4/80+CD86+CD63−↑; M2: F4/80+CD86−CD63+↓; BTZ+ Mouse OA model: M1: (F4/80+CD86+CD63−↑) ↓; M2: (F4/80+CD86−CD63+↓) ↑ | Joint |
Noted:
↑ increase, ↓ decrease, Arg1 Arginase 1, CCL2 chemokine (C–C motif) ligand 2, CCR2 chemokine C–C motif receptor 2, Rheb1 Ras homolog enriched in brain 1
Underlying therapeutic signaling pathway
| Signaling pathway | Interventional site |
|---|---|
| mTORC1-Rheb1/TSC1 [ | Cartilage |
| Sirt1 [ | Cartilage |
| CCL2-CCR2 [ | Cartilage |
| Oxygen and hydrogen peroxide [ | Synovium |
Summary of the detected cell surface marker of M0, M1, and M2 macrophage
| Cell surface marker | |
|---|---|
| M0 macrophage | CD68; F4/80 |
| M1 macrophage | CD86; CD40; iNOS/NOS2; CCR7; CD11c; CD16/32 |
| M2 macrophage | CD163; MRC; CD206; Arg1; CCL22 |
Abbreviation: CCR7 CC-chemokine receptor 7, Arg1 Arginase1, CCL22 C–C motif chemokine ligand 22, iNOS inducible NO synthase, NOS2 NO Synthase2